SNHL is the most prevalent kind of hearing loss. Credit: eltpics / Flickr (Creative Commons).

Frequency Therapeutics has dosed the first subject in the Phase Ib clinical trial of its hearing restoration candidate, FX-345, to treat sensorineural hearing loss (SNHL).

Named FX-345-101, the prospective, single-blind, two-cohort, randomised, placebo-controlled, multicentre trial will assess the safety of single intratympanic doses of FX-345.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It will enrol nearly 36 adult subjects aged 18 to 67 years with adult-onset acquired SNHL. 

The preliminary safety cohort of the trial will have nine subjects to evaluate the safety and drug exposure versus a placebo. 

On obtaining favourable safety data, the second cohort with 27 subjects will receive the treatment to further assess the safety.

See Also:

It will also analyse if FX-345 boosts auditory function measures. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A cocktail of two small molecules, FX-345 is created for restoring inner ear cells required for hearing. 

Frequency Therapeutics CEO David Lucchino said: “Advancing FX-345 to the clinic is an exciting milestone, as we further our pioneering work to develop regenerative therapeutics for hearing loss. 

“By expanding our hearing pipeline, we hope to better understand the breadth of SNHL types and severities we may be able to treat, and we look forward to FX-345 Phase Ib study data in the second half of next year.” 

Apart from FX-345, the company is analysing a therapeutic candidate, FX-322, in a Phase IIb trial underway for SNHL. 

The double-blinded, randomised, placebo-controlled, multicentre trial is intended to assess the efficacy of FX-322 on speech perception in participants aged 18 to 65 years, with hearing loss linked to either noise-induced or permanent idiopathic sudden SNHL. 

This trial has concluded enrolment with 142 subjects, with data anticipated in the first quarter of next year.

A most prevalent kind of hearing loss, SNHL is caused by damage to sensory hair cells in the cochlea.